150 related articles for article (PubMed ID: 33643502)
1. A Pilot Phase II Study of the Feasibility and Efficacy of Vincristine Sulfate Liposome Injection in Patients With Relapsed or Refractory Acute Myeloid Leukemia.
Seegars MB; Woods R; Ellis LR; Bhave RR; Howard DS; Manuel M; Dralle S; Lyerly S; Powell BL; Pardee TS
J Hematol; 2021 Feb; 10(1):1-7. PubMed ID: 33643502
[TBL] [Abstract][Full Text] [Related]
2. High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia.
O'Brien S; Schiller G; Lister J; Damon L; Goldberg S; Aulitzky W; Ben-Yehuda D; Stock W; Coutre S; Douer D; Heffner LT; Larson M; Seiter K; Smith S; Assouline S; Kuriakose P; Maness L; Nagler A; Rowe J; Schaich M; Shpilberg O; Yee K; Schmieder G; Silverman JA; Thomas D; Deitcher SR; Kantarjian H
J Clin Oncol; 2013 Feb; 31(6):676-83. PubMed ID: 23169518
[TBL] [Abstract][Full Text] [Related]
3. Phase 1 multicenter study of vincristine sulfate liposomes injection and dexamethasone in adults with relapsed or refractory acute lymphoblastic leukemia.
Thomas DA; Kantarjian HM; Stock W; Heffner LT; Faderl S; Garcia-Manero G; Ferrajoli A; Wierda W; Pierce S; Lu B; Deitcher SR; O'Brien S
Cancer; 2009 Dec; 115(23):5490-8. PubMed ID: 19708032
[TBL] [Abstract][Full Text] [Related]
4. Vincristine Sulfate Liposomes Injection (VSLI, Marqibo®): Results From a Phase I Study in Children, Adolescents, and Young Adults With Refractory Solid Tumors or Leukemias.
Shah NN; Merchant MS; Cole DE; Jayaprakash N; Bernstein D; Delbrook C; Richards K; Widemann BC; Wayne AS
Pediatr Blood Cancer; 2016 Jun; 63(6):997-1005. PubMed ID: 26891067
[TBL] [Abstract][Full Text] [Related]
5. High-Dose Vincristine Sulfate Liposome Injection, for Advanced, Relapsed, or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia in an Adolescent and Young Adult Subgroup of a Phase 2 Clinical Trial.
Schiller GJ; Damon LE; Coutre SE; Hsu P; Bhat G; Douer D
J Adolesc Young Adult Oncol; 2018 Oct; 7(5):546-552. PubMed ID: 30239252
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of vincristine sulfate liposome injection (Marqibo) and rituximab for patients with relapsed and refractory diffuse large B-Cell lymphoma or mantle cell lymphoma in need of palliative therapy.
Kaplan LD; Deitcher SR; Silverman JA; Morgan G
Clin Lymphoma Myeloma Leuk; 2014 Feb; 14(1):37-42. PubMed ID: 24252360
[TBL] [Abstract][Full Text] [Related]
7. Treating relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia: liposome-encapsulated vincristine.
Davis T; Farag SS
Int J Nanomedicine; 2013; 8():3479-88. PubMed ID: 24072970
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and pharmacodynamics of vincristine sulfate liposome injection (VSLI) in adults with acute lymphoblastic leukemia.
Silverman JA; Reynolds L; Deitcher SR
J Clin Pharmacol; 2013 Nov; 53(11):1139-45. PubMed ID: 23907766
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Vincristine Sulfate Liposome Injection in the Treatment of Adult Acute Lymphocytic Leukemia.
Douer D
Oncologist; 2016 Jul; 21(7):840-7. PubMed ID: 27328933
[TBL] [Abstract][Full Text] [Related]
10. Liposomal vincristine for relapsed or refractory Ph-negative acute lymphoblastic leukemia: a review of literature.
Pathak P; Hess R; Weiss MA
Ther Adv Hematol; 2014 Feb; 5(1):18-24. PubMed ID: 24490021
[TBL] [Abstract][Full Text] [Related]
11. Long term results of a phase 2 study of vincristine sulfate liposome injection (Marqibo(®) ) substituted for non-liposomal vincristine in cyclophosphamide, doxorubicin, vincristine, prednisone with or without rituximab for patients with untreated aggressive non-Hodgkin lymphomas.
Hagemeister F; Rodriguez MA; Deitcher SR; Younes A; Fayad L; Goy A; Dang NH; Forman A; McLaughlin P; Medeiros LJ; Pro B; Romaguera J; Samaniego F; Silverman JA; Sarris A; Cabanillas F
Br J Haematol; 2013 Sep; 162(5):631-8. PubMed ID: 23802738
[TBL] [Abstract][Full Text] [Related]
12. High-dose vincristine sulfate liposome injection (Marqibo) Is not associated with clinically meaningful hematologic toxicity.
Deitcher OR; Glaspy J; Gonzalez R; Sato T; Bedikian AY; Segarini K; Silverman J; Deitcher SR
Clin Lymphoma Myeloma Leuk; 2014 Jun; 14(3):197-202. PubMed ID: 24417913
[TBL] [Abstract][Full Text] [Related]
13. Marqibo® (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine.
Silverman JA; Deitcher SR
Cancer Chemother Pharmacol; 2013 Mar; 71(3):555-64. PubMed ID: 23212117
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic Behavior of Vincristine and Safety Following Intravenous Administration of Vincristine Sulfate Liposome Injection in Chinese Patients With Malignant Lymphoma.
Yang F; Jiang M; Lu M; Hu P; Wang H; Jiang J
Front Pharmacol; 2018; 9():991. PubMed ID: 30210349
[No Abstract] [Full Text] [Related]
15. Pharmacokinetic behavior of vincristine sulfate following administration of vincristine sulfate liposome injection.
Embree L; Gelmon K; Tolcher A; Hudon N; Heggie J; Dedhar C; Logan P; Bally MB; Mayer LD
Cancer Chemother Pharmacol; 1998; 41(5):347-52. PubMed ID: 9523729
[TBL] [Abstract][Full Text] [Related]
16. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
17. A pilot study with vincristine sulfate liposome infusion in patients with metastatic melanoma.
Bedikian AY; Papadopoulos NE; Kim KB; Vardeleon A; Smith T; Lu B; Deitcher SR
Melanoma Res; 2008 Dec; 18(6):400-4. PubMed ID: 19011511
[TBL] [Abstract][Full Text] [Related]
18. Combination of Blinatumomab and Vincristine Sulfate Liposome Injection for Treatment of Relapsed Philadelphia Chromosome Positive B-cell Acute Lymphoblastic Leukemia.
McCusker MG; El Chaer F; Duffy A; Emadi A; Duong VH
Am J Leuk Res; 2018; 2(1):. PubMed ID: 29953129
[TBL] [Abstract][Full Text] [Related]
19. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study.
Perl AE; Altman JK; Cortes J; Smith C; Litzow M; Baer MR; Claxton D; Erba HP; Gill S; Goldberg S; Jurcic JG; Larson RA; Liu C; Ritchie E; Schiller G; Spira AI; Strickland SA; Tibes R; Ustun C; Wang ES; Stuart R; Röllig C; Neubauer A; Martinelli G; Bahceci E; Levis M
Lancet Oncol; 2017 Aug; 18(8):1061-1075. PubMed ID: 28645776
[TBL] [Abstract][Full Text] [Related]
20. Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study.
Goldberg AD; Atallah E; Rizzieri D; Walter RB; Chung KY; Spira A; Stock W; Tallman MS; Cruz HG; Boni J; Havenith KEG; Chao G; Feingold JM; Wuerthner J; Solh M
Leuk Res; 2020 Aug; 95():106385. PubMed ID: 32521310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]